InflammaSense
Develops multimodal, millisecond-resolution physiological monitoring and molecular point-of-care biomarker analytics combined with AI-driven predictive models to enable early detection of hemodynamic compromise and inflammatory disease, and to support patient stratification for clinical trials and treatment selection.
Industries
Nr. of Employees
small (1-50)
Products
Continuous wearable vital-sign monitoring patch (in development)
A wearable patch designed to continuously capture multimodal vital signs and autonomic signals for multiple days per charge, intended for clinical, research, and operational monitoring.
Continuous wearable vital-sign monitoring patch (in development)
A wearable patch designed to continuously capture multimodal vital signs and autonomic signals for multiple days per charge, intended for clinical, research, and operational monitoring.
Services
Provision of multimodal physiological and molecular biomarker analytics to enrich clinical trial cohorts, identify responders early, and improve endpoint sensitivity.
Continuous wearable monitoring and analytics intended to detect hemodynamic decompensation and monitor inflammation in operational settings.
Provision of multimodal physiological and molecular biomarker analytics to enrich clinical trial cohorts, identify responders early, and improve endpoint sensitivity.
Continuous wearable monitoring and analytics intended to detect hemodynamic decompensation and monitor inflammation in operational settings.
Expertise Areas
- Continuous physiological monitoring
- Autonomic nervous system monitoring
- Point-of-care molecular diagnostics
- AI-driven biomarker analytics
Key Technologies
- Electrocardiography (ECG)
- Photoplethysmography (PPG)
- Continuous temperature sensing
- Inertial/body motion sensing
News & Updates
News release referencing company developments (2025).
Coverage of autonomic neurography device (2024).
Coverage related to vagus nerve and related neurotechnology (2023).
Earlier news release referencing company research (2022).
Received validation/funding from BARDA, NIH, and DARPA-supported programs.
Multiple worldwide patent applications filed related to AI-driven biomarker technology.
News release referencing company developments (2025).
Coverage of autonomic neurography device (2024).
Coverage related to vagus nerve and related neurotechnology (2023).
Earlier news release referencing company research (2022).
Received validation/funding from BARDA, NIH, and DARPA-supported programs.
Multiple worldwide patent applications filed related to AI-driven biomarker technology.